Dr. Joseph McGuirk, MD
Claim this profileThe University of Kansas Hospital
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
9 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Joseph McGuirk, MD is currently running
Umbilical Cord Stem Cells
for Graft-versus-Host Disease
This study evaluates the safety and effectiveness of two different doses of umbilical cord derived, ex-vivo cultured and expanded Wharton's jelly mesenchymal stem cells (MSCTC-0010) in the treatment of acute Graft versus Host Disease (aGVHD). The first 5 participants enrolled in the study will receive a lower dose of MSCTC-0010. If none of the first 5 participants have treatment-related serious adverse events (TRSAEs) for 42 days, then the next 5 participants will receive a slightly higher dose of MSCTC-0010.
Recruiting1 award Phase 111 criteria
OrcaGraft
for Blood Cancer
This trial is testing the safety and effectiveness of using specially prepared donor cells for patients with blood cancers. These patients are receiving a strong type of bone marrow transplant. The goal is to replace their damaged bone marrow with healthy cells from a donor to help them recover. Bone marrow transplantation (BMT) is a powerful strategy for the treatment of leukemia, aplastic anemia, congenital immunodeficiency, and autoimmune diseases.
Recruiting1 award Phase 1
More about Joseph McGuirk, MD
Clinical Trial Related5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Joseph McGuirk, MD has experience with
- MSCTC-0010
- Orca-T
- CRG-022
- CTX110
- AUTO1
- EAGD T-cell Infusion
Breakdown of trials Joseph McGuirk, MD has run
T-Lymphoblastic Leukemia/Lymphoma
Acute Lymphoblastic Leukemia
Myeloid Leukemia
Chronic Myelogenous Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Joseph McGuirk, MD specialize in?
Joseph McGuirk, MD focuses on T-Lymphoblastic Leukemia/Lymphoma and Acute Lymphoblastic Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved CD19 positive patients, or patients who are undergoing treatment.
Is Joseph McGuirk, MD currently recruiting for clinical trials?
Yes, Joseph McGuirk, MD is currently recruiting for 3 clinical trials in Kansas City Kansas. If you're interested in participating, you should apply.
Are there any treatments that Joseph McGuirk, MD has studied deeply?
Yes, Joseph McGuirk, MD has studied treatments such as MSCTC-0010, Orca-T, CRG-022.
What is the best way to schedule an appointment with Joseph McGuirk, MD?
Apply for one of the trials that Joseph McGuirk, MD is conducting.
What is the office address of Joseph McGuirk, MD?
The office of Joseph McGuirk, MD is located at: The University of Kansas Hospital, Kansas City, Kansas 66160 United States. This is the address for their practice at the The University of Kansas Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.